Clinical Trials Logo

Clinical Trial Summary

Angiotensin converting enzyme (ACE) inhibitors have been shown to improve survival and to reduce the risk of cardiovascular events in some groups of patients following myocardial infarction. This study is designed to test whether early initiation (≤7 days) of an ACE inhibitor post-coronary artery bypass graft (CABG), would reduce cardiovascular events. The trial was a double-blind, placebo controlled study of 2,553 patients randomly assigned to quinapril, target dose 40 mg daily or placebo, followed up to 43 months.


Clinical Trial Description

The IMAGINE study is a double-blind, placebo controlled, parallel group, randomized, multi-centre international study conducted in patients who have undergone CABG. The research protocol was approved by the ethics committee of all participating institutions, and all patients gave written informed consent. The data were collected and analysed by an independent clinical research organization.

Patients were screened for eligibility and randomized in hospital within seven days post-CABG, except for France where randomization could occur within ten days post-CABG. Starting November 6, 2001, given the increasing evidence of benefit of ACE inhibitors in patients with diabetes and renal disease,14 all patients requiring insulin or with type II diabetes and micro-albuminuria were no longer eligible for the study. Those already in the trial were treated according to the clinical judgement of the treating physician.

Of patients screened in 57 sites in Canada, the Netherlands, Belgium or France, 2 553 patients (approximately 5 percent of patients screened) were randomized post-operatively to quinapril either 10 or 20 mg, or to placebo. Randomization was done centrally, was un-stratified, block-based, and computer generated. If tolerated, patients were up-titrated to 40 mg of quinapril or its placebo equivalent within hospital, or if not tolerated, later post-hospital discharge. Patients were followed for twenty-four months at which time they were invited to continue until 43 months of follow-up, or withdrawn if they did not wish to extend their participation in the trial.

The original primary endpoint consisted of time to first occurrence of any of the composite of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina requiring hospitalization and documented angina not requiring hospitalization. On January 14, 2003, the Steering Committee concluded that the required number of endpoints would likely not be reached without modification of the primary endpoint. Stroke and congestive heart failure requiring hospitalization were thus added to the primary endpoint and sample-size was increased to 2 500 patients.

The secondary endpoints included, 1) time to first occurrence of the following composite of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization or stroke; 2) incidence of any of the above mentioned secondary endpoints; 3) time to first occurrence of the composite primary endpoint with the addition of the following: transient ischemic attack, and any cardiovascular event requiring hospitalization; 4) incidence of any secondary endpoints included in #3; and 5) time to occurrence of death from any cause. All endpoints were adjudicated in a blinded fashion by an endpoint committee, based on pre-defined definitions for each endpoint. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind


Related Conditions & MeSH terms


NCT number NCT00269243
Study type Interventional
Source Montreal Heart Institute
Contact
Status Completed
Phase Phase 4
Start date November 1999
Completion date May 2005

See also
  Status Clinical Trial Phase
Completed NCT01928745 - Experimental Determination of Atot en Ka in the Critically Ill N/A
Completed NCT01956708 - Transfer of Cardioprotection During RIPC N/A
Active, not recruiting NCT00966654 - Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery Phase 2
Completed NCT00524901 - Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia Phase 2
Completed NCT01282671 - Effects of Deep Breathing Exercises Two Months After Cardiac Surgery Phase 2
Completed NCT03050489 - Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Recruiting NCT06124937 - Empagliflozin to Prevent Post-Operative Atrial Fibrillation Phase 3
Recruiting NCT03139929 - Measurement of MSFP and Stressed Volume With CardioQ+®
Active, not recruiting NCT03424941 - The TransCatheter Valve and Vessels Trial N/A
Completed NCT06317363 - Effects of Acapella VS CHEST Physiotherapy in Post-Operative CABG Patients N/A
Completed NCT05023083 - Cross Cultural Adaptation of Functional Status Questionnaire in Urdu Language in CABG Patients
Completed NCT03800264 - Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Phase 4
Completed NCT05285865 - Scapular Mobilization on Inspiratory Capacity of Post-CABG Patients N/A
Not yet recruiting NCT06173609 - Long LIMA Patch on Left Anterior Descending Coronary Artery in CABG
Not yet recruiting NCT06238011 - Dexmedetomidine vs Control on Attenuation Hemodynamic Response to Noxious Stimuli in CABG Surgical Patients N/A
Active, not recruiting NCT06127147 - High-intensity Inspiratory Muscle Training as a Pre-cardiac Rehabilitation in Heart Disease N/A
Recruiting NCT06029556 - Effects of Early Mobility Protocols in Cardiac ICU N/A
Enrolling by invitation NCT01205620 - IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery Phase 2